Lupin launches generic Dasatinib Tablets in US after FDA approval

Regulatory product approvalBusiness Updates View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹2147.00

prior close

₹2084.00

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.1%+0.3% vs market

Pharmaceuticals peers, median of 155sector-0.5%-0.3% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.2

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-1.1+0.3-0.5-0.3

Next day

+1.6+1.8-0.1+1.4+0.2

+2.3+2.4-0.1+1.6+0.7

+3.3+2.1+1.3+0.8+2.5

+0.7+2.0-1.3+0.4+0.3

+2.9+3.6-0.8+2.2+0.7

+3.2+4.1-0.9+2.5+0.7

15d

+4.7+1.8+2.8+0.5+4.2

+7.9-0.1+8.0-1.9+9.8

+5.5-7.8+13.3-6.5+12.0

+9.4+3.1+6.3+3.1+6.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin launched Dasatinib Tablets in 6 strengths (20-140 mg) in the United States after receiving U.S. FDA approval for its ANDA. The drug is a generic of Bristol-Myers Squibb's Sprycel, used to treat Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. It was developed with Pharmascience Inc. The reference brand had estimated annual US sales of about USD 930 million as of Oct 2025.

Likely market impact

Positive — enters a USD 930 million US market with a new oncology generic, supporting future US revenue growth.